Hashimoto M, Hatta W, Tsuji Y, et al. - Since delayed bleeding is a substantial adverse event in endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), researchers assessec the frequency and risk factors of rebleeding in these patients. Among 11,452 individuals who had ESD for EGC at 33 institutions in Japan between 2013 and 2016, 489 patients with delayed bleeding were evaluated. According to findings, rebleeding was seen in 11.2% (55/489) of the recruited patients and the rebleeding rate during discontinuation status was 6.1%, while it was 20.0% in taking warfarin (continuation or resumption). Independent risk factors for rebleeding were warfarin and a resection size >40 mm, as seen in multivariate analysis. Only warfarin discontinuation was significantly linked with rebleeding vs no use of warfarin, though numerous rebleeding events (75.0%) were seen after the resumption of warfarin. In patients who witnessed delayed bleeding after ESD for EGC, rebleeding was not an uncommon occurrence.